Abstract
Essential arterial hypertension is not a disease that would significantly adversely affect patients in their daily activities. At least mostly.
Nonetheless, it has a significant negative impact on cardiovascular morbidity and mortality. The tight correlation with the degree of hypertension, the patient's age and, of course, commorbidities and cardiovascular risk factors is obvious.
Therefore, the goal of hypertensive therapy is not only to try to achieve optimal reduction of blood pressure, but in a broader sense to reduce the risk of the just mentioned consequences, i.e. to reduce morbidity and reduce mortality. The antihypertensive drug urapidil can also be used in pharmacotherapy, the brief description of which is the subject of this article.